Leo Holdings Corp. (LHC) Provides Info on its Potential Target
by Kristi Marvin on 2020-01-27 at 9:47am

Leo Holdings Corp. (LHC), which is headed for an extension vote on February 11th, filed an 8-K this morning providing information on a potential target they are in discussions with for a combination.  These were termed “advanced discussions”, but it sounds like regardless of how far along they are in the process, they won’t be able to get a definitive agreement on file ahead of their shareholder vote to extend.  As such, they are only able to provide some headline details about the company.

Those headline details are that this is a “high-growth, technology-enabled business capitalizing on the secular shift of advertising dollars from traditional offline channels to online digital channels by helping connect consumers and advertisers with innovative marketplace solutions. Leo believes that the target’s financial profile is compelling with significant historical revenue growth, expected revenue growth for 2020 of 30% and strong EBITDA margins and cash conversion.” Additionally, the EV/EBITDA multiple is expected to be 13 time fiscal year 2020 expected EBITDA.

So what can we glean from this new information.  For one, it sounds like Leo Holdings Corp. would like to hang on to their cash in trust, otherwise they wouldn’t have put this information out hoping to pique the interest of investors.  If you recall, LHC is not offering any contribution to trust for non-redeeming shareholders and they are asking for an additional five and a half months.  Typically in those situations, no contribution and a long extension means a SPAC is either trying to reduce their trust value to accommodate a smaller than anticipated target, or they want to replace the cash in trust with a PIPE.  However, in LHC’s case, by providing detail on a pending announcement ahead of their vote, they’re trying to signal “you should reconsider if you were planning on redeeming”.  Nebula was facing similar circumstances, but managed to squeak in their transaction announcement a few days ahead of their extension vote.

However, there’s no guarantee that these advanced talks will lead to a definitive agreement, so it’s a bit of a risk for investors.  Plus, without being able to drill down on all the details, it’s hard to say if LHC’s deal will be a real winner.  Or, if there’s a PIPE involved and at we don’t know at what price. However, the 8-K certainly is intriguing.   The question is, is it intriguing enough to protect their cash in trust?  We have two weeks to find out, but maybe LHC will manage to move the discussions far enough along that we get a real announcement ahead of their vote.

 

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved